While CHOP-R is considered the standard of treatment in front collection treatment of DLBCL.

Cell Therapeutics reports cardiac safety outcomes from phase II trial of pixantrone in CHOP-R regimen Cell Therapeutics, Inc. reported today preliminary cardiac basic safety results from a UNITED STATES randomized phase II trial which substituted pixantrone for doxorubicin in the typical CHOP-R regimen. Called PIX203, the randomized trial compared CPOP-R directly to CHOP-R in the very first line treatment of high risk patients with diffuse large B cell non-Hodgkin’s lymphoma . While CHOP-R is considered the standard of treatment in front collection treatment of DLBCL, exposure to cumulative doses of doxorubicin, an anthracycline, is associated with increasing incidence of irreversible, severe, and symptomatic cardiac toxicity.Twenty % of the trials had been inconsistent between the website and medical journals in how they reported the primary outcomes of the trial. Still, in most cases, these discrepancies were small and did not affect the statistical significance of the total result. Another discrepancy between the two areas of reporting arrived in how deaths that were part of the clinical trials were reported. In that circumstance, deaths seemed to be underreported or inconsistently record on ClinicalTrials.gov. For example, in 17 % of the trials that didn’t reported deaths on ClinicalTrials.gov, deaths were reported in the journal article on the trial. Research have got indicated ClinicalTrials Prior.gov doesn’t have a uniform way of reporting deaths and that may lead to inconsistencies.